HLN
Haleon plc$8.89
LiveJun 08, 2026
Market cap
$39.48B
52w range
8.65 – 11.28
P / E
—
EPS
—
Volume
11.7M
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Haleon plc’s valuationBusiness description
· company · SEC profileHaleon plc
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Founded
—
IPO
Jul 25, 2022
Employees
24,561
HQ
Weybridge
CEO
Brian James McNamara
CFO
—
Exchange
NYSE
Fiscal year
—
Identifiers
· company_identifiersCIK0001900304
CUSIP405552100
ISINUS4055521003
FIGIHLN US
LEI—